MYOV insider filings
Myovant Sciences Ltd. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-03-10. Screen MYOV transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for MYOV between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Myovant Sciences Ltd.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-03-10 | 4 | Valente Nancy — Director | Disposition to issuer (D): 3,673 · Disposition to issuer (D): 36,892 (derivative) | EDGAR |
| 2023-03-10 | 4 | Merendino Lauren — Chief Commercial Officer | Disposition to issuer (D): 21,791 · Disposition to issuer (D): 147,747 · Disposition to issuer (D): 123,300 (derivative) · Disposition to issuer (D): 103,703 (derivative) | EDGAR |
| 2023-03-10 | 4 | Mehra Uneek — Principal Financial Officer | Disposition to issuer (D): 20,724 · Disposition to issuer (D): 181,972 · Disposition to issuer (D): 165,192 (derivative) · Disposition to issuer (D): 111,111 (derivative) | EDGAR |
| 2023-03-10 | 4 | Lang Matthew — General Counsel & Corp. Secy. | Disposition to issuer (D): 113,145 · Disposition to issuer (D): 241,158 · Disposition to issuer (D): 220,000 (derivative) · Disposition to issuer (D): 87,050 (derivative) · Disposition to issuer (D): 152,110 (derivative) · Disposition to issuer (D): 170,396 (derivative) · +2 more | EDGAR |
| 2023-03-10 | 4 | Curran Terrie — Director | Disposition to issuer (D): 3,673 · Disposition to issuer (D): 33,846 (derivative) · Disposition to issuer (D): 11,154 (derivative) · Disposition to issuer (D): 22,500 (derivative) · Disposition to issuer (D): 22,500 (derivative) · Disposition to issuer (D): 5,250 (derivative) · +2 more | EDGAR |
| 2023-03-10 | 4 | Arjona Ferreira Juan Camilo — Chief Medical Officer | Disposition to issuer (D): 86,602 · Disposition to issuer (D): 160,082 · Disposition to issuer (D): 155,300 (derivative) · Disposition to issuer (D): 63,717 (derivative) · Disposition to issuer (D): 65,863 (derivative) · Disposition to issuer (D): 134,464 (derivative) · +2 more | EDGAR |
| 2023-03-10 | 4 | Gulfo Adele M. — Director | Disposition to issuer (D): 3,673 · Disposition to issuer (D): 45,000 (derivative) · Disposition to issuer (D): 21,603 (derivative) · Disposition to issuer (D): 21,096 (derivative) | EDGAR |
| 2023-03-10 | 4 | Marek David C — Principal Executive Officer, Director | Disposition to issuer (D): 95,675 · Disposition to issuer (D): 321,924 · Disposition to issuer (D): 306,427 (derivative) · Disposition to issuer (D): 208,218 (derivative) · Disposition to issuer (D): 204,808 (derivative) · Disposition to issuer (D): 134,567 (derivative) | EDGAR |
| 2023-03-10 | 4 | GUINAN MARK — Director | Disposition to issuer (D): 3,673 · Disposition to issuer (D): 45,000 (derivative) · Disposition to issuer (D): 58,608 (derivative) · Disposition to issuer (D): 21,603 (derivative) · Disposition to issuer (D): 21,096 (derivative) | EDGAR |
| 2023-03-10 | 4 | Sumitomo Chemical Co., Ltd. — 10% owner Sumitomo Pharma Co., Ltd. — 10% owner Sumitovant Biopharma Ltd. — 10% owner | Purchase (P): 51,599,200 @ $27 | EDGAR |
| 2023-03-10 | 4 | POTTER MYRTLE S — Director | Disposition to issuer (D): 3,673 · Disposition to issuer (D): 45,000 (derivative) · Disposition to issuer (D): 58,608 (derivative) · Disposition to issuer (D): 21,603 (derivative) · Disposition to issuer (D): 21,096 (derivative) | EDGAR |
| 2023-03-06 | 4 | Sumitomo Chemical Co., Ltd. — 10% owner Sumitomo Pharma Co., Ltd. — 10% owner Sumitovant Biopharma Ltd. — 10% owner | Other (J): 4,243,005 @ $0 · Other (J): 1 (derivative) @ $0 | EDGAR |
| 2023-01-20 | 4 | Lang Matthew — General Counsel & Corp. Secy. | Sale (S): 1,272 @ $26.89 | EDGAR |
| 2023-01-20 | 4 | Merendino Lauren — Chief Commercial Officer | Sale (S): 2,008 @ $26.89 | EDGAR |
| 2023-01-20 | 4 | Arjona Ferreira Juan Camilo — Chief Medical Officer | Sale (S): 1,109 @ $26.89 | EDGAR |
| 2023-01-20 | 4 | Marek David C — Principal Executive Officer, Director | Sale (S): 8,037 @ $26.89 | EDGAR |
| 2023-01-05 | 4 | Arjona Ferreira Juan Camilo — Chief Medical Officer | Sale (S): 2,251 @ $26.90 | EDGAR |
| 2023-01-05 | 4 | Lang Matthew — General Counsel & Corp. Secy. | Sale (S): 2,779 @ $26.90 | EDGAR |
| 2022-12-20 | 4 | Mehra Uneek — Principal Financial Officer | Sale (S): 2,241 @ $26.75 | EDGAR |
| 2022-10-28 | 4 | Curran Terrie — Director | Grant/award (A): 9,859 @ $0 | EDGAR |
| 2022-10-28 | 4 | Valente Nancy — Director | Grant/award (A): 9,859 @ $0 | EDGAR |
| 2022-10-28 | 4 | Gulfo Adele M. — Director | Grant/award (A): 9,859 @ $0 | EDGAR |
| 2022-10-28 | 4 | GUINAN MARK — Director | Grant/award (A): 9,859 @ $0 | EDGAR |
| 2022-10-28 | 4 | POTTER MYRTLE S — Director | Grant/award (A): 9,859 @ $0 | EDGAR |
| 2022-10-20 | 4 | Merendino Lauren — Chief Commercial Officer | Sale (S): 1,703 @ $25.20 | EDGAR |
| 2022-10-20 | 4 | Lang Matthew — General Counsel & Corp. Secy. | Sale (S): 1,933 @ $25.20 | EDGAR |
| 2022-10-20 | 4 | Arjona Ferreira Juan Camilo — Chief Medical Officer | Sale (S): 1,604 @ $25.20 | EDGAR |
| 2022-10-20 | 4 | Marek David C — Principal Executive Officer, Director | Sale (S): 11,156 @ $25.20 | EDGAR |
| 2022-10-06 | 4 | Arjona Ferreira Juan Camilo — Chief Medical Officer | Sale (S): 2,738 @ $24.40 | EDGAR |
| 2022-10-06 | 4 | Lang Matthew — General Counsel & Corp. Secy. | Sale (S): 3,679 @ $24.40 | EDGAR |
| 2022-09-20 | 4 | Mehra Uneek — Principal Financial Officer | Sale (S): 9,243 @ $18.86 | EDGAR |
| 2022-08-16 | 4 | Lang Matthew — General Counsel & Corp. Secy. | Grant/award (A): 124,780 @ $0 · Sale (S): 31,214 @ $18.23 | EDGAR |
| 2022-07-20 | 4 | Lang Matthew — General Counsel & Corp. Secy. | Sale (S): 1,935 @ $12.87 | EDGAR |
| 2022-07-20 | 4 | Merendino Lauren — Chief Commercial Officer | Sale (S): 1,704 @ $12.87 | EDGAR |
| 2022-07-20 | 4 | Arjona Ferreira Juan Camilo — Chief Medical Officer | Sale (S): 1,606 @ $12.87 | EDGAR |
| 2022-07-20 | 4 | Marek David C — Principal Executive Officer, Director | Sale (S): 11,164 @ $12.87 | EDGAR |
| 2022-07-08 | 4 | Arjona Ferreira Juan Camilo — Chief Medical Officer | Sale (S): 2,755 @ $13.40 | EDGAR |
| 2022-07-08 | 4 | Lang Matthew — General Counsel & Corp. Secy. | Sale (S): 3,702 @ $13.40 | EDGAR |
| 2022-06-01 | 4 | Arjona Ferreira Juan Camilo — Chief Medical Officer | Sale (S): 1,382 @ $10.07 | EDGAR |
| 2022-04-21 | 4 | Lang Matthew — General Counsel & Corp. Secy. | Sale (S): 8,002 @ $10.45 | EDGAR |
| 2022-04-21 | 4 | Arjona Ferreira Juan Camilo — Chief Medical Officer | Sale (S): 4,632 @ $10.45 | EDGAR |
| 2022-04-21 | 4 | Merendino Lauren — Chief Commercial Officer | Sale (S): 7,049 @ $10.45 | EDGAR |
| 2022-04-21 | 4 | Marek David C — Principal Executive Officer, Director | Sale (S): 24,594 @ $10.45 | EDGAR |
| 2022-04-19 | 4 | Mehra Uneek — Principal Financial Officer | Grant/award (A): 111,111 @ $0 | EDGAR |
| 2022-04-19 | 4 | Arjona Ferreira Juan Camilo — Chief Medical Officer | Grant/award (A): 103,703 @ $0 | EDGAR |
| 2022-04-19 | 4 | Lang Matthew — General Counsel & Corp. Secy. | Grant/award (A): 111,111 @ $0 | EDGAR |
| 2022-04-19 | 4 | Merendino Lauren — Chief Commercial Officer | Grant/award (A): 103,703 @ $0 | EDGAR |
| 2022-04-19 | 4 | Marek David C — Principal Executive Officer, Director | Grant/award (A): 134,567 @ $0 · Grant/award (A): 204,808 (derivative) @ $0 | EDGAR |
| 2022-04-07 | 4 | Lang Matthew — General Counsel & Corp. Secy. | Sale (S): 2,436 @ $13.78 | EDGAR |
| 2022-04-07 | 4 | Arjona Ferreira Juan Camilo — Chief Medical Officer | Sale (S): 1,922 @ $13.78 | EDGAR |
Recent 8-K events — Myovant Sciences Ltd.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2023-03-10 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-03-01 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2023-01-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-10-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-10-24 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-10-21 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2022-10-03 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-07-27 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-05-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-03-25 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MYOV returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs